Published in J Biomol Screen on October 01, 2003
The use of AlphaScreen technology in HTS: current status. Curr Chem Genomics (2008) 1.49
Sequence requirement and subtype specificity in the high-affinity interaction between human frizzled and dishevelled proteins. Protein Sci (2009) 0.92
Current Screens Based on the AlphaScreen Technology for Deciphering Cell Signalling Pathways. Curr Genomics (2009) 0.91
Characterization of EPPIN's semenogelin I binding site: a contraceptive drug target. Biol Reprod (2012) 0.77
Development of an HTS-compatible assay for discovery of RORα modulators using AlphaScreen® technology. J Biomol Screen (2011) 0.75
A luminescent oxygen channeling biosensor that measures small GTPase activation. Chem Commun (Camb) (2011) 0.75
In vitro generation of infectious scrapie prions. Cell (2005) 6.86
Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med (2005) 5.05
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA (2003) 4.84
Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J Biol Chem (2006) 2.98
A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95
Prion strain mutation determined by prion protein conformational compatibility and primary structure. Science (2010) 2.71
Detection of prions in blood. Nat Med (2005) 2.66
Cellular imaging in drug discovery. Nat Rev Drug Discov (2006) 2.52
Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J (2003) 2.34
Cell-free propagation of prion strains. EMBO J (2008) 2.20
Presymptomatic detection of prions in blood. Science (2006) 2.14
Crossing the species barrier by PrP(Sc) replication in vitro generates unique infectious prions. Cell (2008) 2.09
Protein misfolding cyclic amplification for diagnosis and prion propagation studies. Methods Enzymol (2006) 2.04
Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem (2002) 2.02
Accelerated high fidelity prion amplification within and across prion species barriers. PLoS Pathog (2008) 1.89
Isolation and characterization of a proteinase K-sensitive PrPSc fraction. Biochemistry (2006) 1.86
Detection of infectious prions in urine. FEBS Lett (2008) 1.85
De novo generation of infectious prions in vitro produces a new disease phenotype. PLoS Pathog (2009) 1.83
Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N Engl J Med (2014) 1.74
The disulfide isomerase Grp58 is a protective factor against prion neurotoxicity. J Neurosci (2005) 1.74
Production of cattle lacking prion protein. Nat Biotechnol (2006) 1.63
Studies on G-protein alpha.betagamma heterotrimer formation reveal a putative S-prenyl-binding site in the alpha subunit. Biochem J (2003) 1.61
Unfolded protein response transcription factor XBP-1 does not influence prion replication or pathogenesis. Proc Natl Acad Sci U S A (2008) 1.60
Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem (2006) 1.54
Stressing out the ER: a role of the unfolded protein response in prion-related disorders. Curr Mol Med (2006) 1.49
Cyclic amplification of protein misfolding and aggregation. Methods Mol Biol (2005) 1.48
TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol (2007) 1.48
Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med (2009) 1.44
Deriving a germinal center lymphocyte migration model from two-photon data. J Exp Med (2008) 1.44
Estimating prion concentration in fluids and tissues by quantitative PMCA. Nat Methods (2010) 1.40
The prion strain phenomenon: molecular basis and unprecedented features. Biochim Biophys Acta (2006) 1.39
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39
Germinal center B cells govern their own fate via antibody feedback. J Exp Med (2013) 1.36
Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem (2003) 1.34
Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci (2010) 1.33
Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation (2006) 1.31
Prion protein glycosylation is not required for strain-specific neurotropism. J Virol (2009) 1.31
In vivo generation of neurotoxic prion protein: role for hsp70 in accumulation of misfolded isoforms. PLoS Genet (2009) 1.29
Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2010) 1.28
Amyloid formation modulates the biological activity of a bacterial protein. J Biol Chem (2005) 1.27
Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol (2011) 1.25
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother (2008) 1.21
In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol (2007) 1.14
Perturbation of endoplasmic reticulum homeostasis facilitates prion replication. J Biol Chem (2007) 1.13
Generation of a new form of human PrP(Sc) in vitro by interspecies transmission from cervid prions. J Biol Chem (2011) 1.12
Prion protein misfolding affects calcium homeostasis and sensitizes cells to endoplasmic reticulum stress. PLoS One (2010) 1.11
Deep sequencing of phage display libraries to support antibody discovery. Methods (2013) 1.11
Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J (2002) 1.11
Structural basis for selective inhibition of Mycobacterium tuberculosis protein tyrosine phosphatase PtpB. Structure (2007) 1.10
Is loss of function of the prion protein the cause of prion disorders? Trends Mol Med (2003) 1.10
Protein misfolding cyclic amplification of infectious prions. Nat Protoc (2012) 1.10
Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog (2013) 1.10
High-resolution structure of infectious prion protein: the final frontier. Nat Struct Mol Biol (2012) 1.09
Cellular factors implicated in prion replication. FEBS Lett (2010) 1.07
Convergent functional genomics of oligodendrocyte differentiation identifies multiple autoinhibitory signaling circuits. Mol Cell Biol (2009) 1.05
Prion replication alters the distribution of synaptophysin and caveolin 1 in neuronal lipid rafts. Am J Pathol (2004) 1.04
Identification and characterization of novel small molecules as potent inhibitors of the plasmodial calcium-dependent protein kinase 1. Biochemistry (2009) 1.02
Osteopontin is upregulated during in vivo demyelination and remyelination and enhances myelin formation in vitro. Mol Cell Neurosci (2004) 1.00
Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J Biol Chem (2007) 1.00
Increased endogenous carbon monoxide production in severe sepsis. Intensive Care Med (2002) 0.99
Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. J Immunol (2003) 0.99
CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur Heart J (2011) 0.98
Cross currents in protein misfolding disorders: interactions and therapy. CNS Neurol Disord Drug Targets (2009) 0.98
Bactericidal activity of both secreted and nonsecreted microcin E492 requires the mannose permease. J Bacteriol (2006) 0.96
Mining biomarker information in biomedical literature. BMC Med Inform Decis Mak (2012) 0.94
Effect of Toll-like receptor 4 blockade on pulmonary inflammation caused by mechanical ventilation and bacterial endotoxin. Exp Lung Res (2008) 0.93
Passage of murine scrapie prion protein across the mouse vascular blood-brain barrier. Biochem Biophys Res Commun (2004) 0.92
Microcin amyloid fibrils A are reservoir of toxic oligomeric species. J Biol Chem (2012) 0.91
Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. Nat Commun (2013) 0.90
Glycosaminoglycan analogs as a novel anti-inflammatory strategy. Front Immunol (2012) 0.89
Changes in the glycosylation pattern of prion protein in murine scrapie. Implications for the mechanism of neurodegeneration in prion diseases. J Biol Chem (2002) 0.89
Protein-tyrosine phosphatase H1 controls growth hormone receptor signaling and systemic growth. J Biol Chem (2007) 0.88
Transferring the characteristics of naturally occurring and biased antibody repertoires to human antibody libraries by trapping CDRH3 sequences. PLoS One (2012) 0.88
Generation of prions in vitro and the protein-only hypothesis. Prion (2010) 0.88
Chemokines derived from soluble fusion proteins expressed in Escherichia coli are biologically active. Biochem Biophys Res Commun (2005) 0.88
Role of calcineurin in neurodegeneration produced by misfolded proteins and endoplasmic reticulum stress. Curr Opin Cell Biol (2011) 0.88
A cellular assay for measuring the modulation of glucose production in H4IIE cells. Assay Drug Dev Technol (2006) 0.88
Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival. PLoS Pathog (2010) 0.88
Recent US Case of Variant Creutzfeldt-Jakob Disease-Global Implications. Emerg Infect Dis (2015) 0.86
Molecular mechanisms of neurotoxicity of pathological prion protein. Curr Mol Med (2004) 0.86
3D and 4D imaging of immune cells in vitro and in vivo. Histochem Cell Biol (2008) 0.85
Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J Immunol Methods (2011) 0.85
Computational selection of inhibitors of Abeta aggregation and neuronal toxicity. Bioorg Med Chem (2009) 0.85
Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J Med Chem (2008) 0.84
Cyclic amplification of prion protein misfolding. Methods Mol Biol (2012) 0.84
Identification of VHY/Dusp15 as a regulator of oligodendrocyte differentiation through a systematic genomics approach. PLoS One (2012) 0.83
The DRY motif as a molecular switch of the human oxytocin receptor. Biochemistry (2005) 0.83
Kosmotropic anions promote conversion of recombinant prion protein into a PrPSc-like misfolded form. PLoS One (2012) 0.81
De novo isolation of antibodies with pH-dependent binding properties. MAbs (2015) 0.81
Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments. Arthritis Rheum (2012) 0.81
Natural animal models of neurodegenerative protein misfolding diseases. Curr Pharm Des (2012) 0.81
Initial fate of prions upon peripheral infection: half-life, distribution, clearance, and tissue uptake. FASEB J (2011) 0.79
Enhancement of islet engraftment and achievement of long-term islet allograft survival by Toll-like receptor 4 blockade. Transplantation (2015) 0.79
HIV/AIDS: modified stem cells in the spotlight. Cell Mol Life Sci (2014) 0.79
Emerging roles of the unfolded protein response signaling in physiology and disease. Curr Mol Med (2006) 0.79
Maturation of human tripeptidyl-peptidase I in vitro. J Biol Chem (2004) 0.79
Comparing CDRH3 diversity captured from secondary lymphoid organs for the generation of recombinant human antibodies. MAbs (2013) 0.79
Epitope-dependent inhibition of T cell activation by the Ea transgene: an explanation for transgene-mediated protection from murine lupus. J Immunol (2004) 0.78
A cellular assay for measuring the inhibition of glycogen synthase kinase-3 via the accumulation of beta-catenin in Chinese hamster ovary clone K1 cells. Assay Drug Dev Technol (2006) 0.78